drugset
drugset / Trial / NCT00910117

Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT00910117 ↗

Phase 2 Completed 40 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to evaluate the role of nimotuzumab in the neo-adjuvant setting in patients with locally advanced HNSCC. The hypothesis is that the response would be increased with the combination of nimotuzumab and cisplatin and fluorouracil (PF) regimen.

Timeline

Start
2009-05
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 400 mg —
Background Cisplatin Other / unclassified 75 mg/m2 —
Background fluorouracil Small molecule 750 mg/m2 Intravenous

Indications

head and neck squamous cell carcinoma